4.8 Article

A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against heterologous lethal Lassa fever

期刊

CELL REPORTS
卷 40, 期 3, 页码 -

出版社

CELL PRESS
DOI: 10.1016/j.celrep.2022.111094

关键词

-

向作者/读者索取更多资源

The study shows that vaccination with a recombinant vesicular stomatitis virus vector can provide rapid protection in monkeys challenged with a genetically heterologous LASV strain from Nigeria. The vaccine not only activates adaptive immunity quickly but also induces the transcription of natural killer cell-affiliated mRNAs.
Lassa virus (LASV) is recognized by the World Health Organization as one of the top five pathogens likely to cause a severe outbreak. A recent unprecedented resurgence of LASV in Nigeria caused by genetically diverse strains underscores the need for licensed medical countermeasures. Single-injection vaccines that can rapidly control outbreaks and confer long-term immunity are needed. Vaccination of cynomolgus mon-keys with a recombinant vesicular stomatitis virus vector expressing the glycoprotein precursor of LASV line-age IV strain Josiah (rVSVDG-LASV-GPC) induces fast-acting protection in monkeys challenged 3 or 7 days later with a genetically heterologous lineage II isolate of LASV from Nigeria, while nonspecifically vaccinated control animals succumb to challenge. The rVSVDG-LASV-GPC vaccine induces rapid activation of adaptive immunity and the transcription of natural killer (NK) cell-affiliated mRNAs. This study demonstrates that rVSVDG-LASV-GPC may provide rapid protection in humans against LASV infections in cases where imme-diate public-health intervention is required.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据